Amicus Therapeutics Inc (FRA:AM6)
€ 9.3 0.2 (2.2%) Market Cap: 2.82 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 16.43 GF Score: 78/100

Amicus Therapeutics Inc Analyst Day Transcript

Oct 10, 2019 / 12:30PM GMT
Release Date Price: €6.7 (-2.90%)
Sara Pellegrino
Amicus Therapeutics, Inc. - VP of IR & Corporate Communications

Good morning, everyone. Welcome to our Amicus Analyst Day 2019. I'm Sara Pellegrino, Head of Investor Relations, and would like to welcome everybody here today.

We will be making forward-looking statements during this Analyst Day, so we'll reference Slide 2. For those of you who are listening remotely, the slides are available right now on the IR section of our website, if you want to follow along with the presentation.

We have a very full agenda this morning, and so we want to make sure that we move through in a timely manner so that we can cover all of the topics that we would like to get to. We'll be covering the vision, mission and strategy. We'll be providing a financial and operational strategy and outlook. We'll be covering Galafold and the road map to $1 billion in sales and include some patient perspectives there. We'll also cover AT-GAA, our crown jewel for Pompe disease as well as our next-generation research and Gene Therapy Program and a special feature on our Batten disease gene therapy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot